65,437 trials
Human Immunodeficiency Virus
Primary: Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12…
Smoking Cessation
Primary: Report's Impact on Calling a Quitline Number
Pediatric Patients With Solid Tumors
Primary: % of Patients in Whom a Sentinel Lymph Node is Identified
Obstructive Sleep Apnea of Adult
Primary: Time (Number of Days) From When Participant is Told They May Have OSA to When They Receive HST Prescription — 7.4 days
Craniopharyngioma · Hypothalamic Obesity
Primary: Weight Loss — 88.3; 91.9; 1.2; 0.9 kg — p=0.92
Migraine
Primary: Migraine Functional Impact Questionnaire (MFIQ) - "Overall Impact on Usual Activities" Scores at Baseline and at End of Treatment (Treatment Month 3). — 43.64; 21.82…
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 64; 74 Participants
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Acute Kidney Injury (AKI)
Primary: Percentage of Participants Developing AKI Based on Serum Creatinine (SCr) Criteria Within 72 Hrs From End of Surgery (AKI-SCr72h) — 24.6; 21.0 percentage of participants…
Arterial Calcification · CD73 Deficiency
Primary: Ankle-brachial Index at Rest at Pre-treatment, On-treatment and Post-treatment of Etidronate in Participants Diagnosed With ACDC — 0.5741; 0.5411; 0.5222; 0.5266 score…
Covid19
Primary: Proper Face Mask Use up to 60 Minutes — 58; 52 Participants
Healthy Volunteers
Primary: Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide — 217.2; 237.2; 221.9; 253.0…
Smoking Cessation
Primary: Percentage of Participants With Self-reported Prolonged Abstinence at 6 Weeks — 4.2; 4.2 percentage of participants
Lung Cancer · Mesothelioma
Primary: Disease Control Rate at 4 Months — 8 Participants
Oral Mucositis
Primary: Feasibility of Photo Biomodulation Therapy (PBM) in Reducing Oral Mucositis (OM) in Children and Adolescents at Risk for Grade 3 OM Undergoing an Allogeneic…